Is the fu­ture of di­a­betes drugs in dual GIP and GLP-1 in­cretin re­cep­tor ag­o­nists? That's the $47M ques­tion for Car­mot

Near­ly three years af­ter clos­ing its Se­ries B, Car­mot Ther­a­peu­tics has re­turned to the fundrais­ing well with a new round. And this time they brought phar­ma gi­ant Am­gen in­to the fold.

The Berke­ley, CA-based biotech an­nounced Thurs­day the com­ple­tion of $47 mil­lion in Se­ries C fi­nanc­ing to boost de­vel­op­ment of pro­grams tar­get­ing in­cretins for the treat­ment of meta­bol­ic dis­eases. Most of the fund­ing will take Car­mot’s lead can­di­date — tar­get­ing GIP and GLP-1 — through Phase II stud­ies start­ing in ear­ly 2021 and a sec­ond pro­gram through Phase I and II tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER